MX2023009701A - Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo. - Google Patents

Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo.

Info

Publication number
MX2023009701A
MX2023009701A MX2023009701A MX2023009701A MX2023009701A MX 2023009701 A MX2023009701 A MX 2023009701A MX 2023009701 A MX2023009701 A MX 2023009701A MX 2023009701 A MX2023009701 A MX 2023009701A MX 2023009701 A MX2023009701 A MX 2023009701A
Authority
MX
Mexico
Prior art keywords
dioxo
tetrahydro
dichloro
oxy
oxo
Prior art date
Application number
MX2023009701A
Other languages
English (en)
Inventor
Mahmoud Mirmehrabi
Marco Jonas
Pavan Karthik Batchu
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of MX2023009701A publication Critical patent/MX2023009701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona a formas mórficas, cocristales, sales y dispersiones sólidas amorfas del 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)ox i)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitril o.
MX2023009701A 2018-07-02 2021-01-06 Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo. MX2023009701A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862692914P 2018-07-02 2018-07-02

Publications (1)

Publication Number Publication Date
MX2023009701A true MX2023009701A (es) 2023-08-29

Family

ID=67441642

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000107A MX2021000107A (es) 2018-07-02 2019-07-02 Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo.
MX2023009701A MX2023009701A (es) 2018-07-02 2021-01-06 Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000107A MX2021000107A (es) 2018-07-02 2019-07-02 Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidro piridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-tria zin-6-carbonitrilo.

Country Status (12)

Country Link
US (1) US20210122740A1 (es)
EP (1) EP3818057A1 (es)
JP (1) JP2021530456A (es)
KR (1) KR20210027454A (es)
CN (1) CN112638904A (es)
AR (1) AR115666A1 (es)
AU (1) AU2019298236A1 (es)
CA (1) CA3104860A1 (es)
IL (1) IL279700A (es)
MX (2) MX2021000107A (es)
TW (1) TW202019914A (es)
WO (1) WO2020010068A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907926T3 (es) 2012-09-17 2022-04-27 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US11090308B2 (en) 2016-10-18 2021-08-17 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
JP7445996B2 (ja) 2019-02-21 2024-03-08 ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用
PE20220255A1 (es) 2019-05-08 2022-02-16 Aligos Therapeutics Inc Moduladores de thr y metodos de uso de estos
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN114787153A (zh) * 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CA3192243A1 (en) 2020-09-10 2022-03-17 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of resmetirom, preparation method therefor, and use thereof
WO2022086894A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
WO2022225827A1 (en) * 2021-04-21 2022-10-27 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1919878T3 (pl) * 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
ES2907926T3 (es) * 2012-09-17 2022-04-27 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US11090308B2 (en) * 2016-10-18 2021-08-17 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist

Also Published As

Publication number Publication date
WO2020010068A1 (en) 2020-01-09
MX2021000107A (es) 2021-05-27
IL279700A (en) 2021-03-01
TW202019914A (zh) 2020-06-01
AU2019298236A1 (en) 2021-01-21
KR20210027454A (ko) 2021-03-10
AR115666A1 (es) 2021-02-10
JP2021530456A (ja) 2021-11-11
CA3104860A1 (en) 2020-01-09
CN112638904A (zh) 2021-04-09
US20210122740A1 (en) 2021-04-29
EP3818057A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
MX2023009701A (es) Formas solidas de 2-(3,5-dicloro-4-( (5-isopropil-6-oxo -1,6-dihidropiridazin-3-il) oxi) fenil)-3,5-dioxo -2,3,4,5-tetrahidro -1,2,4-triazina-6-carbonitrilo.
CL2017000705A1 (es) Nuevos compuestos
MX2019004492A (es) Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta.
GEP20237506B (en) Pcsk9 antagonist compounds
EA201992300A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА
PH12020551464A1 (en) Cd73 inhibitors
MA40481A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante
PH12019501068A1 (en) Crystalline forms of a magl inhibitor
NZ607845A (en) Besylate salt of a btk inhibitor
MA39001A1 (fr) Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn?
PH12019502037A1 (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
CL2008002038A1 (es) Compuestos derivados de 3-fenil-1,2-oxazol, inhibidores de canales de sodio; y su uso para el tratamiento de un trastorno de dolor.
EA202191422A1 (ru) Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
PH12017501948A1 (en) Novelty crystal of uracil compound
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
NZ722624A (en) Fused pyrimidines as inhibitors of p97 complex
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
MX2017015257A (es) Cristal de (6s, 9as)-n-bencil-8-({6-[3-(4-etilpiperazin-1-il)azeti din-1-il]piridin-2-il}metil)-6-(2-(fluoruro-4-hidroxibencil)-4,7- dioxo-2-prop-2-en-1-il)hexahidro-2h-pirazino[2,1-c] [1,2,4]triazon-1-(6h)-carboxamida.
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
ECSP18030976A (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento
MX2016017405A (es) Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
CL2021000797A1 (es) Una ayuda para la deposición de fluidos agrícolas.